New Progress of Epigenetic Biomarkers in Urological Cancer.
Urological cancers consist of bladder, kidney, prostate, and testis cancers and they are generally silenced at their early stage, which leads to the loss of the best opportunity for early diagnosis and treatment. Desired biomarkers are scarce for urological cancers and current biomarkers are lack of specificity and sensitivity. Epigenetic alterations are characteristic of nearly all kinds of human malignances including DNA methylation, histone modification, and miRNA regulation. Besides, the detection of these epigenetic conditions is easily accessible especially for urine, best target for monitoring the diseases of urinary system. Here, we summarize some new progress about epigenetic biomarkers in urological cancers, hoping to provide new thoughts for the diagnosis, treatment, and prognosis of urological cancers.
Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China; Shenzhen Following Precision Medical Institute, Shenzhen Luohu Hospital Group, Shenzhen 518000, China; First Clinical Medical College, Anhui Medical University, Hefei 230032, China; Shenzhen Second People's Hospital, 1st Affiliated Hospital of Shenzhen University, Shenzhen 518037, China.
Peng
0000-0001-9932-0757
P
Wu
Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China; Shenzhen Following Precision Medical Institute, Shenzhen Luohu Hospital Group, Shenzhen 518000, China; Shenzhen Second People's Hospital, 1st Affiliated Hospital of Shenzhen University, Shenzhen 518037, China; Medical College, Shenzhen University, Shenzhen 518060, China.
Ziyi
Z
Cao
Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China; Shenzhen Following Precision Medical Institute, Shenzhen Luohu Hospital Group, Shenzhen 518000, China; Shenzhen Second People's Hospital, 1st Affiliated Hospital of Shenzhen University, Shenzhen 518037, China; Shenzhen Gene Detection Public Service Platform of Clinical Application, Shenzhen Luohu Hospital Group, Shenzhen 518000, China.
Song
0000-0001-6751-6325
S
Wu
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics*; D044127:Epigenesis, Genetic / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011237:Predictive Value of Tests; D014571:Urologic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy
D014408:Biomarkers, Tumor